OBJECTIVES To examine the feasibility of using milrinone to test pulmonary vascular reactivity in patients before heart transplantation, we tested the hypothesis that milrinone would lower pulmonary vascular resistance (PVR) in patients with severe heart failure. BACKGROUND Fixed pulmonary hypertension is a risk factor for right heart failure and death after orthotopic heart transplantation. ...

This investigation evaluated the effect of continuous milrinone infusion on right ventricular (RV) function during off-pump coronary artery bypass graft (OPCAB) surgery in patients with reduced RV function. Fifty patients scheduled for OPCAB, with thermodilution RV ejection fraction (RVEF) <35% after anesthesia induction, were randomly allocated to either milrinone (0.5 microg/kg/min) or contro...

UNLABELLED Amrinone and milrinone are phosphodiesterase inhibitors with positive inotropic effects useful for the treatment of ventricular dysfunction after cardiac surgery. Forty-four patients undergoing elective cardiac surgery at four centers received either amrinone (n = 22) or milrinone (n = 22) in a randomized, blind fashion. Immediately after separation from cardiopulmonary bypass (CPB),...

BACKGROUND Ischemic postconditioning (PostC) protects the liver against ischemia-reperfusion (IR) injury. Milrinone, a phosphodiesterase 3 inhibitor, has been reported to exhibit preconditioning properties against hepatic IR injury; however, its PostC properties remain unknown. This study investigated whether milrinone has PostC properties against hepatic IR injury and the roles of phosphatidyl...

Yano, Masafumi, Michihiro Kohno, Tomoko Ohkusa, Mamoru Mochizuki, Jutaro Yamada, Masateru Kohno, Takayuki Hisaoka, Kaoru Ono, Taketo Tanigawa, Shigeki Kobayashi, and Masunori Matsuzaki. Effect of milrinone on left ventricular relaxation and Ca uptake function of cardiac sarcoplasmic reticulum. Am J Physiol Heart Circ Physiol 279: H1898–H1905, 2000.—Milrinone, a phosphodiesterase 3 (PDE3) inhibi...

BACKGROUND The use of parenteral positive inotropic agents still remains a major component of therapy for patients with advanced decompensated congestive heart failure (CHF). However, no consensus guidelines have been developed for the appropriate selection of a first-line inotropic therapy. We sought to compare the clinical outcome and economic cost of dobutamine-based and milrinone-based ther...

BACKGROUND: Our aim is to check effectiveness of intravenous Levosimendan in comparison with intravenous Milrinone in congenital heart surgery with cardiopulmonary bypass. MATERIALS AND METHODS: 50 Paediatric patients between 2 months to 12 years of age divided into two groups. Group L (n=25) received inj. levosimendan 12μg/kg over 10 minutes1 after cross clamp removal and 0.1μg/kg/min started ...

The effects of milrinone, a new bipyridine inotropic agent, on the haemodynamic responses to treadmill exercise were studied in 12 patients with congestive heart failure. Four weeks' treatment with milrinone 20 mg daily produced an improvement in left ventricular function during exercise as reflected by significant increments in cardiac index and stroke volume index without change in pulmonary ...

OBJECTIVES The goal of this study was to assess the interaction between heart failure (HF) etiology and response to milrinone in decompensated HF. BACKGROUND Etiology has prognostic and therapeutic implications in HF, but its relationship to response to inotropic therapy is unknown. METHODS The Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failu...

Aerosolized prostacyclin (PGI2) produces selective pulmonary vasodilation in patients with pulmonary hypertension (PH). The response to PGI2 may be increased by phosphodiesterase type 3 inhibitors such as milrinone. We studied the dose response effects of aerosolized PGI2 and aerosolized milrinone both alone and in combination on pulmonary and systemic hemodynamics in newborn lambs with Nomega-...